

VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001073

Report Form

Serious Adverse Event Report Form

Please send this report immediately to Assign Safety Desk via:

Fax: +43 (0) 512 281514 77 or e-mail: SafetyDesk@assigndmb.com

(24h Safety Hotline: +43 (0) 676 844033835)

All dates should be provided as DD/MMM/YYYY.

1. PROTOCOL INFORMATION:		
Protocol Short Title:	VLN Cigarette Consumption Study	IND no.: N/A
Celerion Protocol no.:	CA24914	Country: USA
2. REPORTER'S DETAILS:		
Reporter's name:	(b) (6)	
Address:	621 Rose St. Lincoln, NE 68502	
Site:	Celerion	
Email:	(b) (6) @ celerion.com	
Phone/Fax:	(b) (6)	
3. REPORT INFORMATION: (please use the same form for initial and follow-up report, if possible)		
Initial Report:	Date: 17 SEP 2018	(b) (6)
	dd mm yy	Reporter's name and Signature
Follow-Up No.:	Date: 20	Reporter's name and Signature
	dd mm yy	
Follow-Up No.:	Date: 20	Reporter's name and Signature
	dd mm yy	
Follow-Up No.:	Date: 20	Reporter's name and Signature
	dd mm yy	
4. SUBJECT INFORMATION:		
Date of birth:	Race:	Height:
(b) (6)	<input checked="" type="checkbox"/> White/Caucasian	1.61 cm
	<input type="checkbox"/> Black/African American	
	<input type="checkbox"/> Asian	
	<input type="checkbox"/> Native Hawaiian/other Pacific Islander	
	<input type="checkbox"/> American Indian/Alaska Native	
	<input type="checkbox"/> Other:	
Gender:		Weight:
<input checked="" type="checkbox"/> female		62.6 kg
<input type="checkbox"/> male		

VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001023

Report Form

5. SERIOUS ADVERSE EVENT: (short term; please provide ONE diagnosis, if possible)

Subarachnoid hemorrhage

6. SERIOUS ADVERSE EVENT INFORMATION:

Awareness date: 17 SEP 2018 Date the investigator became aware of the event
 Onset date of event: (b) (6) Date the event started, i.e. the first symptoms occurred
 Stop date of event: 20 Date, when the event (including symptoms) subsided, stabilized with sequelae, or date of subject's death

7. SEVERITY OF SAE:

☐ Mild ☐ Moderate ☒ Severe
8. SERIOUSNESS CRITERIA: (please tick all that apply) ☐ yes ☐ no (non-serious event of special interest)

- ☒ Inpatient hospitalization or prolongation of existing hospitalization* ☐ Persistent or significant disability/incapacity or substantial interruption to conduct normal life functions
☐ Congenital anomaly/birth defect ☒ Life-threatening
☒ Important medical event ☐ Death**
 (Please specify in the SAE description field on page 3 and only tick this criterion if no other applies)

* if hospitalization: Date of admission: (b) (6) Date of discharge: 20
 dd mm yyyy dd mm yyyy

** if death: Date of death: 20
 dd mm yyyy

Probable cause of death: _____ Autopsy performed? ☐ yes ☐ no
 (if yes, please provide summary of autopsy report in the SAE description on page 3)

9. SAE OUTCOME: (please tick only one)

- ☐ resolved ☐ worse
☐ improved ☐ fatal
☐ unchanged ☐ unknown/lost to follow-up

VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001023

Report Form

10. STUDY PRODUCT INFORMATION:

Study product name	First use			Last use prior to SAE		
	dd	mmm	yyyy	dd	mmm	yyyy
<input type="checkbox"/> Subject's usual brand non-mentholated filtered king size cigarettes			20			20
<input type="checkbox"/> Subject's usual brand mentholated filtered king size cigarettes			20			20
<input checked="" type="checkbox"/> Non-mentholated VLN cigarettes	02	AUG	2018	14	SEP	2018
<input type="checkbox"/> Mentholated VLN cigarettes			20			20

11. ASSESSMENT OF CAUSALITY:

☐ likely ☐ probably ☐ possibly ☐ unlikely ☐ unrelated

12. ACTION TAKEN WITH STUDY PRODUCT: (please tick only one)

☐ Unchanged ☐ Interrupted ☐ Reduced ☐ Withdrawn

13. ACTION TAKEN TO TREAT SAE:

☐ none
☐ drug therapy started
☐ diagnostic test performed
☐ non-drug therapy started
☒ unknown

☐ other (please specify):

14. SERIOUS ADVERSE EVENT DESCRIPTION:

Describe event fully. Include baseline medical status (medical history, signs and symptoms, diagnosis, diagnostic test results, clinical course, treatment (all drugs/procedures used as interventions for SAE), outcome, hospital course for hospitalizations, etc.
Please do not attach test results and hospital records but provide a short summary of relevant findings. Please also provide rationale for relationship assessment.

On (b) (6) Subject 001023 was admitted to the hospital. According to her son, it was for a subarachnoid hemorrhage. The son stated that she underwent medical procedures to drain the blood in her brain. The physician said that there's at least a 10 day recovery time. Celerion was notified of this SAE on 17SEP2018

Confidential

Subject ID

SAE

22nd Century Group, Inc.

--	--	--	--	--	--

Report Form

This image shows a single sheet of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page. There is no handwriting or other markings on the paper.

15. INVESTIGATOR'S SIGNATURE:

Investigator's name: PHILIP MATHEW

Investigator's signature: _____

(b) (6)

Date:

17 SEP 2018
dd mmm yyyy

FOR DRUG SAFETY DEPARTMENT ONLY - NOT TO BE FILLED IN BY REPORTER:

Received date: 18-Sep-2018

Time: 01:52

Tracked: ☒

Case Number:

VLCN-Student-001-023-01

Signature:

(b) (6)